Fibroblast proliferation and apoptosis pathways

Fibroblast proliferation and apoptosis pathways represent the integrated signaling networks that control the growth, activation, and programmed death of fibroblasts, which are the primary cells responsible for maintaining tissue integrity and the extracellular matrix (Source: NIH/NCBI). These pathways involve a variety of growth factors and cytokines, most notably Transforming Growth Factor-beta (TGF-beta), Platelet-Derived Growth Factor (PDGF), and Fibroblast Growth Factor (FGF), which drive the transition of fibroblasts into contractile myofibroblasts (Source: PubMed, PMID: 30214015). Apoptosis in these cells is tightly regulated by the balance of pro-apoptotic and anti-apoptotic BCL-2 family proteins, as well as extrinsic signals like the Fas/FasL system (Source: Journal of Clinical Investigation). In pathological states such as idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and certain cancers, these pathways become dysregulated, leading to uncontrolled fibroblast expansion and resistance to cell death, resulting in excessive scarring and organ dysfunction (Source: StatPearls). Therapeutic strategies targeting these pathways often utilize multi-kinase inhibitors or monoclonal antibodies to block upstream receptors or neutralize key ligands, thereby slowing disease progression (Source: FDA). Common drugs like Nintedanib and Pirfenidone act by interfering with these signaling cascades to reduce the fibroproliferative response and promote a more homeostatic environment (Source: Mayo Clinic).

Other names

Fibroblast signaling pathwaysFibroproliferative pathwaysMyofibroblast activation and survival pathways

Inhibition of receptor tyrosine kinases (VEGFR, FGFR, PDGFR) and modulation of pro-fibrotic cytokines like TGF-beta to inhibit fibroblast activation and survival (Source: PubMed, PMID: 25144854).